About Dry Eye Syndrome Drugs
Dry eye syndrome, also known as keratoconjunctivitis sicca, is the condition of having dry eyes where either the eyes are not capable of producing sufficient tears to maintain lubrication or the when produced, they evaporate too quickly. The condition can lead to various difficulties in the daily life of a person, such as reading for an extended period of time or using a computer. The condition can decrease the tolerance of a person in a dry environment such as air present inside an airplane.
Technavio’s analysts forecast the global dry eye syndrome drugs market to grow at a CAGR of 7.59% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global dry eye syndrome drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Dry Eye Syndrome Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Allergan
• Novartis
• Otsuka Holdings
• Santen Pharmaceutical
Other prominent vendors
• Aerie Pharmaceutical
• Akorn
• Bausch & Lomb
• Johnson & Johnson
• Merck
• MIMETOGEN
• ReGenTree
• Sun Pharmaceutical
• Teva Pharmaceutical
Market driver
• Untapped potential in developing countries
• For a full, detailed list, view our report
Market challenge
• Lack of ophthalmology experts
• For a full, detailed list, view our report
Market trend
• Initiatives and programs for supporting patients with ophthalmic disorders
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Five forces analysis
PART 06: PIPELINE LANDSCAPE
PART 07: MARKET SEGMENTATION BY PRODUCT
• OTC drugs
• Prescription drugs
PART 08: REGIONAL LANDSCAPE
• Regional comparison
• Dry eye syndrome drugs market in Americas
• Dry eye syndrome drugs market in EMEA
• Dry eye syndrome drugs market in APAC
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Initiatives and programs for supporting patients with ophthalmic disorders
• Advancement in diagnostic techniques for dry eye syndrome
PART 12: VENDOR LANDSCAPE
PART 13: KEY VENDOR ANALYSIS
• Allergan
• Otsuka Holdings
• Novartis
• Santen Pharmaceutical
• Other prominent vendors
PART 14: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Market share of ophthalmic drugs market 2016
Exhibit 02: Causes of dry eyes
Exhibit 03: Symptoms, diagnosis, and treatment of dry eyes
Exhibit 04: Dry eye syndrome drugs market: Snapshot
Exhibit 05: Global dry eye syndrome drugs market 2016-2021 ($ millions)
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline molecules in Phase III by vendors
Exhibit 08: Key clinical trials
Exhibit 09: Global dry eye syndrome drugs market by product 2016-2021 (% share)
Exhibit 10: Global dry eye syndrome drugs market by OTC drugs 2016-2021 ($ millions)
Exhibit 11: Qualities of OTC drugs present in the market
Exhibit 12: OTC drugs based on inclusion of preservatives
Exhibit 13: Global dry eye syndrome drugs market by prescription drugs 2016-2021 ($ millions)
Exhibit 14: Regional landscape
Exhibit 15: Regional comparison
Exhibit 16: Dry eye syndrome drugs market in Americas 2016-2021 ($ millions)
Exhibit 17: Dry eye syndrome drugs market in Americas – Year over year growth
Exhibit 18: Dry eye syndrome drugs market in EMEA 2016-2021 ($ millions)
Exhibit 19: Dry eye syndrome drugs market in EMEA – Year over year growth
Exhibit 20: Dry eye syndrome drugs market in APAC 2016-2021 ($ millions)
Exhibit 21: Dry eye syndrome drugs market in APAC – Year over year growth
Exhibit 22: Key leading countries
Exhibit 23: World population by age group: 2015-2050
Exhibit 24: Percentage of population aged 60 and above by region 2015-2050
Exhibit 25: Risk factors for developing dry eye syndrome in older population
Exhibit 26: Demographic and economic snapshot of India and China
Exhibit 27: Factors causing autoimmune disorders
Exhibit 28: Top concerns of health insurance in US
Exhibit 29: Competitive structure analysis of global dry eye syndrome drugs market 2016
Exhibit 30: Vendor landscape for global dry eye syndrome drugs market 2016-2021
Exhibit 31: Allergan: Key highlights
Exhibit 32: Allergan: Strength assessment
Exhibit 33: Allergan: Strategy assessment
Exhibit 34: Allergan: Opportunity assessment
Exhibit 35: Otsuka Holdings: Key highlights
Exhibit 36: Otsuka Holdings: Strength assessment
Exhibit 37: Otsuka Holdings: Strategy assessment
Exhibit 38: Otsuka Holdings: Opportunity assessment
Exhibit 39: Novartis: Key highlights
Exhibit 40: Novartis: Strength assessment
Exhibit 41: Novartis: Strategy assessment
Exhibit 42: Novartis: Opportunity assessment
Exhibit 43: Santen Pharmaceutical: Key highlights
Exhibit 44: Santen Pharmaceutical: Strength assessment
Exhibit 45: Santen Pharmaceutical: Strategy assessment
Exhibit 46: Santen Pharmaceutical: Opportunity assessment
